182 related articles for article (PubMed ID: 27507877)
21. Beyond oncology: Selinexor's journey into anti-inflammatory treatment and long-term management.
Li D; Fang H; Zhang R; Xie Q; Yang Y; Chen L
Front Immunol; 2024; 15():1398927. PubMed ID: 38799428
[TBL] [Abstract][Full Text] [Related]
22. Selinexor for Refractory Multiple Myeloma.
Jhaveri KD; Wanchoo R
N Engl J Med; 2019 Nov; 381(20):1977. PubMed ID: 31722162
[No Abstract] [Full Text] [Related]
23. Selinexor for Refractory Multiple Myeloma. Reply.
Chari A; Vogl DT; Jagannath S
N Engl J Med; 2019 Nov; 381(20):1977-1978. PubMed ID: 31722163
[No Abstract] [Full Text] [Related]
24. Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Kilburn LB; Khuong-Quang DA; Hansford JR; Landi D; van der Lugt J; Leary SES; Driever PH; Bailey S; Perreault S; McCowage G; Waanders AJ; Ziegler DS; Witt O; Baxter PA; Kang HJ; Hassall TE; Han JW; Hargrave D; Franson AT; Yalon Oren M; Toledano H; Larouche V; Kline C; Abdelbaki MS; Jabado N; Gottardo NG; Gerber NU; Whipple NS; Segal D; Chi SN; Oren L; Tan EEK; Mueller S; Cornelio I; McLeod L; Zhao X; Walter A; Da Costa D; Manley P; Blackman SC; Packer RJ; Nysom K
Nat Med; 2024 May; 30(5):1500. PubMed ID: 38467878
[No Abstract] [Full Text] [Related]
25. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
27. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
Garzon R; Savona M; Baz R; Andreeff M; Gabrail N; Gutierrez M; Savoie L; Mau-Sorensen PM; Wagner-Johnston N; Yee K; Unger TJ; Saint-Martin JR; Carlson R; Rashal T; Kashyap T; Klebanov B; Shacham S; Kauffman M; Stone R
Blood; 2017 Jun; 129(24):3165-3174. PubMed ID: 28336527
[TBL] [Abstract][Full Text] [Related]
28. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
[No Abstract] [Full Text] [Related]
29. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
Kuruvilla J; Savona M; Baz R; Mau-Sorensen PM; Gabrail N; Garzon R; Stone R; Wang M; Savoie L; Martin P; Flinn I; Jacoby M; Unger TJ; Saint-Martin JR; Rashal T; Friedlander S; Carlson R; Kauffman M; Shacham S; Gutierrez M
Blood; 2017 Jun; 129(24):3175-3183. PubMed ID: 28468797
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
Wang AY; Weiner H; Green M; Chang H; Fulton N; Larson RA; Odenike O; Artz AS; Bishop MR; Godley LA; Thirman MJ; Kosuri S; Churpek JE; Curran E; Pettit K; Stock W; Liu H
J Hematol Oncol; 2018 Jan; 11(1):4. PubMed ID: 29304833
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.
Gupta A; Saltarski JM; White MA; Scaglioni PP; Gerber DE
J Thorac Oncol; 2017 Sep; 12(9):1446-1450. PubMed ID: 28647672
[TBL] [Abstract][Full Text] [Related]
32. Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study.
Bhatnagar B; Zhao Q; Mims AS; Vasu S; Behbehani GK; Larkin K; Blachly JS; Blum W; Klisovic RB; Ruppert AS; Orwick S; Oakes C; Ranganathan P; Byrd JC; Walker AR; Garzon R
Leuk Lymphoma; 2020 Feb; 61(2):387-396. PubMed ID: 31545113
[TBL] [Abstract][Full Text] [Related]
33. Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.
Nilsson S; Stein A; Rolfo C; Kranich AL; Mann J; Papadimitriou K; Theile S; Amberg S; Bokemeyer C
Curr Cancer Drug Targets; 2020; 20(10):811-817. PubMed ID: 32598257
[TBL] [Abstract][Full Text] [Related]
34. Selinexor for the treatment of multiple myeloma.
Podar K; Shah J; Chari A; Richardson PG; Jagannath S
Expert Opin Pharmacother; 2020 Mar; 21(4):399-408. PubMed ID: 31957504
[No Abstract] [Full Text] [Related]
35. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Taylor J; Mi X; Penson AV; Paffenholz SV; Alvarez K; Sigler A; Chung SS; Rampal RK; Park JH; Stein EM; Tallman MS; Sen F; Gönen M; Abdel-Wahab O; Klimek VM
Lancet Haematol; 2020 Aug; 7(8):e566-e574. PubMed ID: 32735836
[TBL] [Abstract][Full Text] [Related]
36. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N; Maerevoet M; Cavallo F; Follows G; Goy A; Vermaat JSP; Casasnovas O; Hamad N; Zijlstra JM; Bakhshi S; Bouabdallah R; Choquet S; Gurion R; Hill B; Jaeger U; Sancho JM; Schuster M; Thieblemont C; De la Cruz F; Egyed M; Mishra S; Offner F; Vassilakopoulos TP; Warzocha K; McCarthy D; Ma X; Corona K; Saint-Martin JR; Chang H; Landesman Y; Joshi A; Wang H; Shah J; Shacham S; Kauffman M; Van Den Neste E; Canales MA
Lancet Haematol; 2020 Jul; 7(7):e511-e522. PubMed ID: 32589977
[TBL] [Abstract][Full Text] [Related]
37. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Sweet K; Komrokji R; Padron E; Cubitt CL; Turner JG; Zhou J; List AF; Sallman DA; Dawson JL; Sullivan DM; Chavez J; Shah BD; Lancet JE
Clin Cancer Res; 2020 Jan; 26(1):54-60. PubMed ID: 31636097
[TBL] [Abstract][Full Text] [Related]
38. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S; Dimopoulos M; Stewart AK; Richter J; Vij R; Tuchman S; Raab MS; Weisel KC; Delforge M; Cornell RF; Kaminetzky D; Hoffman JE; Costa LJ; Parker TL; Levy M; Schreder M; Meuleman N; Frenzel L; Mohty M; Choquet S; Schiller G; Comenzo RL; Engelhardt M; Illmer T; Vlummens P; Doyen C; Facon T; Karlin L; Perrot A; Podar K; Kauffman MG; Shacham S; Li L; Tang S; Picklesimer C; Saint-Martin JR; Crochiere M; Chang H; Parekh S; Landesman Y; Shah J; Richardson PG; Jagannath S
N Engl J Med; 2019 Aug; 381(8):727-738. PubMed ID: 31433920
[TBL] [Abstract][Full Text] [Related]
39. XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB.
Galinski B; Luxemburg M; Landesman Y; Pawel B; Johnson KJ; Master SR; Freeman KW; Loeb DM; Hébert JM; Weiser DA
Transl Oncol; 2021 Aug; 14(8):101114. PubMed ID: 33975179
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]